Transmural Systems Announces New Board-Level Appointments

October 15, 2024—Transmural Systems, a developer of devices for transcatheter electrosurgery to treat structural heart failure, announced that Jeffrey B. Jump has been named Executive Chairman and Simos Kedikoglou has been appointed Board Director. Both have many years of experience in the medical device industry, specializing in the cardiovascular sector.

According to the company, Jump was most recently Chairman and CEO of MedAlliance, which was acquired by Cordis in October 2023. Previously, he was CEO of Biosensors, where he spent 15 years. He has been a chairman or board member of 15 companies, resulting in three initial public offerings and seven trade sales, including Symetis in the transcatheter aortic valve replacement space.

Kedikoglou was CEO of Impulse Dynamics, a heart failure company, and a board member of MedAlliance. Previously, he was the Corporate Vice President of Business Development at Boston Scientific.

“I am pleased to welcome both Jeff and Simos, who will help us focus on accelerating growth by executing new strategies to expand structural heart procedures and benefit patients around the world,” commented Transmural’s CEO and Founder, Nasser Rafiee, in the company’s press release.

Jeffrey Jump added, “I have been impressed by the unique platform of structural heart and electrosurgical therapies that Transmural Systems has developed. They have positioned themselves to provide interventional cardiologists with the opportunity to treat many more patients that would have otherwise required complicated surgical or medical interventions.”

Jump continued, “Over the past 10 years, Nasser, in collaboration with a team of pioneering structural heart failure physicians and engineers, has created innovative, disruptive, intuitive, safe, and effective therapies for the structural heart space.”

As noted in the press release, Transmural has developed three structural heart platforms:

• Telltale, an interventional tool for leaflet modification. Telltale has received FDA Breakthrough designation and aims to expand patient access for aortic and mitral valve procedures. The first United States TELLTALE clinical trial is nearing full enrollment and is expected to undergo FDA review early next year.
• Sesame, a transcatheter myotomy system that addresses a need for hypertrophic cardiomyopathy and manages left ventricular flow obstruction.
• Mirth, a myocardial intramural remodeling ventriculoplasty system that narrows the left ventricle circumferentially using controlled intramyocardial navigation to treat heart failure with reduced ejection fraction.